{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:22:08Z","timestamp":1792225328861,"version":"4.4.0"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,6,15]],"date-time":"2010-06-15T00:00:00Z","timestamp":1276560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>A phase II A study was conducted to evaluate the safety and efficacy of Givinostat, a novel Histone\u2010Deacetylases inhibitor, in patients with Polycythaemia Vera (PV, <jats:italic>n<\/jats:italic>\u2003=\u200312), Essential Thrombocythaemia (ET, <jats:italic>n<\/jats:italic>\u2003=\u20031) and Myelofibrosis (<jats:italic>n<\/jats:italic>\u2003=\u200316), bearing the JAK2V617F mutation. The study was approved by the local ethics committees and all human participants gave written informed consent. Givinostat was given orally for 24\u2003weeks at a starting dose of 50\u2003mg twice daily. The median treatment duration was 20\u2003weeks. Reasons for treatment discontinuation were disease progression (<jats:italic>n<\/jats:italic>\u2003=\u20036), grade 2 thrombocytopenia (<jats:italic>n<\/jats:italic>\u2003=\u20031), psychiatric symptoms (<jats:italic>n<\/jats:italic>\u2003=\u20031) and withdrawn consent (<jats:italic>n<\/jats:italic>\u2003=\u20032). A dose reduction was applied in 10 patients while a temporary interruption occurred in 15. Among 13 PV\/ET patients, 1 complete, 6 partial and 4 no responses were documented at study end while 2 patients went off\u2010study, prematurely. Three major responses were registered among 16 MF patients. Pruritus disappeared in most patients and reduction of splenomegaly was observed in 75% of PV\/ET and 38% of MF patients. Reverse transcription polymerase chain reaction identified a trend to reduction of the <jats:italic>JAK2<\/jats:italic>V617F allele burden. Givinostat was well tolerated and could induce haematological response in most PV and some MF patients.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2010.08266.x","type":"journal-article","created":{"date-parts":[[2010,6,16]],"date-time":"2010-06-16T03:33:27Z","timestamp":1276659207000},"page":"446-455","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":216,"title":["A pilot study of the Histone\u2010Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms"],"prefix":"10.1111","volume":"150","author":[{"given":"Alessandro","family":"Rambaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Maria","family":"Dellacasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Finazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Carobbio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Gattoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Salmoiraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Finazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Di Tollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"D\u2019Urzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Barosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210820"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1520"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404473"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08019.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-176818"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood.V112.11.2586.2586","article-title":"Phase II trial of combination of the Histone Deacetylase inhibitor ITF2357 and Meclorethamine demonstrates clinical activity and safety in heavily pretreated patients with relapsed\/refractory Hodgkin Lymphoma (HL)","volume":"112","author":"Carlo\u2010Stella C.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-014126"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0793-8"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404860"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405049"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13721"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V114.22.754.754","article-title":"A multicenter, open label Phase I\/II study of CEP701 (Lestaurtinib) in adults with myelofibrosis; a report on Phase I: a study of the Myeloproliferative Disorders Research Consortium (MPD\u2010RC)","volume":"114","author":"Hexner E.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.280"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210677"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0640-3"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.2119\/2006-00005.Dinarello"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1182\/blood.V114.22.753.753","article-title":"An open\u2010label study of CEP\u2010701 in patients with JAK2 V617F\u2010Positive PV and ET: update of 39 enrolled patients","volume":"114","author":"Moliterno A.R.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood.V114.22.755.755","article-title":"A Phase I evaluation of TG101348, a selective JAK2 inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F Allele burden","volume":"114","author":"Pardanani A.D.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009746"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083501"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.7356"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.012088"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood.V114.22.311.311","article-title":"A Phase 2 study of INCB018424, an oral, selective JAK1\/JAK2 inhibitor, in patients with advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea","volume":"114","author":"Verstovsek S.","year":"2009","journal-title":"Blood"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2010.08266.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2010.08266.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T12:30:17Z","timestamp":1697373017000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2010.08266.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1111\/j.1365-2141.2010.08266.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08266.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"2010-08-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}